UY30559A1 - Derivados de morfolino pirimidina, procesos de preparacion, composiciones conteniéndolos y aplicaciones - Google Patents
Derivados de morfolino pirimidina, procesos de preparacion, composiciones conteniéndolos y aplicacionesInfo
- Publication number
- UY30559A1 UY30559A1 UY30559A UY30559A UY30559A1 UY 30559 A1 UY30559 A1 UY 30559A1 UY 30559 A UY30559 A UY 30559A UY 30559 A UY30559 A UY 30559A UY 30559 A1 UY30559 A1 UY 30559A1
- Authority
- UY
- Uruguay
- Prior art keywords
- compositions containing
- pirimidina
- morfolino
- derivatives
- applications
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
- C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
- C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
- C07D239/32—One oxygen, sulfur or nitrogen atom
- C07D239/42—One nitrogen atom
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
- C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
Abstract
Un compuesto de formula (I) o una sal farmacéuticamente aceptable del mismo, procesos para su preparacion, composiciones farmacéuticas que los contienen y su uso en terapia, por ejemplo en el tratamiento de una enfermedad proliferativa tal como cáncer y particularmente en una enfermedad mediada por una mTOR quinasa y/o una enzima PI3K.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
GB0616747A GB0616747D0 (en) | 2006-08-24 | 2006-08-24 | Novel compounds |
US94854407P | 2007-07-09 | 2007-07-09 |
Publications (1)
Publication Number | Publication Date |
---|---|
UY30559A1 true UY30559A1 (es) | 2008-03-31 |
Family
ID=38720451
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
UY30559A UY30559A1 (es) | 2006-08-24 | 2007-08-23 | Derivados de morfolino pirimidina, procesos de preparacion, composiciones conteniéndolos y aplicaciones |
Country Status (16)
Country | Link |
---|---|
US (1) | US7750003B2 (es) |
EP (1) | EP2057140B1 (es) |
JP (1) | JP5534811B2 (es) |
KR (1) | KR101435231B1 (es) |
AR (1) | AR062526A1 (es) |
AU (1) | AU2007287428B2 (es) |
CA (1) | CA2660758A1 (es) |
CL (1) | CL2007002446A1 (es) |
CO (1) | CO6150160A2 (es) |
HK (1) | HK1130776A1 (es) |
IL (1) | IL196998A0 (es) |
MX (1) | MX2009002046A (es) |
NO (1) | NO20090631L (es) |
PE (1) | PE20081362A1 (es) |
UY (1) | UY30559A1 (es) |
WO (1) | WO2008023159A1 (es) |
Families Citing this family (75)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
ATE456836T1 (de) * | 1996-09-04 | 2010-02-15 | Intertrust Tech Corp | Zuverlässige infrastrukturhilfssysteme, verfahren und techniken für sicheren elektronischen handel, elektronische transaktionen, handelsablaufsteuerung und automatisierung, verteilte verarbeitung und rechteverwaltung |
US7935715B2 (en) | 2006-07-28 | 2011-05-03 | Boehringer Ingelheim International Gmbh | Compounds which modulate the CB2 receptor |
KR101435231B1 (ko) | 2006-08-24 | 2014-10-02 | 아스트라제네카 아베 | 증식성 질환의 치료에 유용한 모르폴리노 피리미딘 유도체 |
AU2007300295A1 (en) | 2006-09-25 | 2008-04-03 | Boehringer Ingelheim International Gmbh | Compounds which modulate the CB2 receptor |
CA2673652A1 (en) * | 2007-01-09 | 2008-07-17 | Amgen Inc. | Bis-aryl amide derivatives and methods of use |
ATE551334T1 (de) * | 2007-02-06 | 2012-04-15 | Novartis Ag | Pi3-kinase-hemmer und verfahren zu ihrer verwendung |
EA018708B1 (ru) | 2007-07-09 | 2013-10-30 | Астразенека Аб | ПРОИЗВОДНЫЕ МОРФОЛИНОПИРИМИДИНА, ИСПОЛЬЗУЕМЫЕ ПРИ ЗАБОЛЕВАНИЯХ, СВЯЗАННЫХ С mTOR КИНАЗОЙ И/ИЛИ PI3K |
WO2009007748A2 (en) * | 2007-07-09 | 2009-01-15 | Astrazeneca Ab | Trisubstituted pyrimidine derivatives for the treatment of proliferative diseases |
JP5492092B2 (ja) | 2007-11-07 | 2014-05-14 | ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング | Cb2受容体を調節する化合物 |
JP5581219B2 (ja) | 2008-01-25 | 2014-08-27 | ミレニアム ファーマシューティカルズ, インコーポレイテッド | チオフェンおよびホスファチジルイノシトール3−キナーゼ(pi3k)阻害薬としてのその使用 |
CN101981003B (zh) | 2008-02-29 | 2014-07-02 | 伊沃泰克股份公司 | 酰胺化合物、组合物及其应用 |
US20120015988A1 (en) * | 2008-05-13 | 2012-01-19 | Boehringer Ingelheim International Gmbh | Sulfone Compounds Which Modulate The CB2 Receptor |
AP2775A (en) * | 2008-05-23 | 2013-09-30 | Wyeth Llc | Triazine compounds as P13 kinase and MTOR inhibitors |
EP2313399B1 (en) * | 2008-06-19 | 2014-05-28 | Millennium Pharmaceuticals, Inc. | Thiophene or thiazole derivatives and their use as pi3k inhibitors |
EP2326629B1 (en) | 2008-07-10 | 2013-10-02 | Boehringer Ingelheim International GmbH | Sulfone compounds which modulate the cb2 receptor |
JP2011529920A (ja) | 2008-07-31 | 2011-12-15 | ジェネンテック, インコーポレイテッド | ピリミジン化合物、組成物及び使用方法 |
WO2010030027A1 (en) | 2008-09-10 | 2010-03-18 | Mitsubishi Tanabe Pharma Corporation | Aromatic nitrogen-containing 6-membered ring compounds and their use |
CA2737038A1 (en) | 2008-09-18 | 2010-03-25 | Evotec Ag | Amide compounds, compositions and uses thereof |
EA201100523A1 (ru) | 2008-09-25 | 2011-10-31 | Бёрингер Ингельхайм Интернациональ Гмбх | Соединения сульфонила, которые селективно модулируют рецептор св2 |
TWI378933B (en) | 2008-10-14 | 2012-12-11 | Daiichi Sankyo Co Ltd | Morpholinopurine derivatives |
US20110053923A1 (en) | 2008-12-22 | 2011-03-03 | Astrazeneca | Chemical compounds 610 |
CN102395585A (zh) | 2009-01-30 | 2012-03-28 | 米伦纽姆医药公司 | 杂芳基化合物和其作为pi3k抑制剂的用途 |
US8796314B2 (en) | 2009-01-30 | 2014-08-05 | Millennium Pharmaceuticals, Inc. | Heteroaryls and uses thereof |
US9090601B2 (en) | 2009-01-30 | 2015-07-28 | Millennium Pharmaceuticals, Inc. | Thiazole derivatives |
ES2529205T3 (es) | 2009-03-13 | 2015-02-17 | Cellzome Limited | Derivados de pirimidina como inhibidores de mTOR |
WO2010120991A1 (en) * | 2009-04-17 | 2010-10-21 | Wyeth Llc | 5, 6, 7, 8-tetrahydropyrido[4,3-d]pyrimidine compounds, their use as mtor, pi3, and hsmg-1 kinase inhibitors, and their syntheses |
WO2010120998A1 (en) * | 2009-04-17 | 2010-10-21 | Wyeth Llc | Pyrimidine compounds, their use as mtor kinase and pi3 kinase inhibitors, and their syntheses |
WO2010120996A1 (en) * | 2009-04-17 | 2010-10-21 | Wyeth Llc | 5,6,7,8-tetrahydropyrido[3,4-d]pyrimidine compounds, their use as mtor kinase and pi3 kinase inhibitors, and their syntheses |
JPWO2010125799A1 (ja) * | 2009-04-27 | 2012-10-25 | 塩野義製薬株式会社 | Pi3k阻害活性を有するウレア誘導体 |
US8299103B2 (en) | 2009-06-15 | 2012-10-30 | Boehringer Ingelheim International Gmbh | Compounds which selectively modulate the CB2 receptor |
JP5756800B2 (ja) | 2009-06-16 | 2015-07-29 | ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング | Cb2受容体を調節するアゼチジン2−カルボキサミド誘導体 |
NZ619259A (en) * | 2009-06-17 | 2015-07-31 | Vertex Pharma | Inhibitors of influenza viruses replication |
SG176959A1 (en) * | 2009-06-24 | 2012-01-30 | Genentech Inc | Oxo-heterocycle fused pyrimidine compounds, compositions and methods of use |
EP2480544A1 (en) | 2009-09-22 | 2012-08-01 | Boehringer Ingelheim International GmbH | Compounds which selectively modulate the cb2 receptor |
EP2493460A4 (en) | 2009-10-30 | 2013-04-24 | Ariad Pharma Inc | METHOD AND COMPOSITIONS FOR THE TREATMENT OF CANCER |
US8288381B2 (en) | 2009-11-12 | 2012-10-16 | Genentech, Inc. | N-9 substituted purine compounds, compositions and methods of use |
KR101447789B1 (ko) | 2009-11-12 | 2014-10-06 | 에프. 호프만-라 로슈 아게 | N-7 치환된 퓨린 및 피라졸로피리미딘 화합물, 조성물 및 사용 방법 |
US9315491B2 (en) | 2009-12-28 | 2016-04-19 | Development Center For Biotechnology | Pyrimidine compounds as mTOR and PI3K inhibitors |
US9315454B2 (en) | 2010-01-15 | 2016-04-19 | Boehringer Ingelheim International Gmbh | Compounds which modulate the CB2 receptor |
ES2535116T3 (es) | 2010-03-04 | 2015-05-05 | Cellzome Limited | Derivados de urea sustituida con morfolino como inhibidores de mtor |
US8329735B2 (en) | 2010-03-05 | 2012-12-11 | Boehringer Ingelheim International Gmbh | Tetrazole compounds which selectively modulate the CB2 receptor |
SA111320519B1 (ar) | 2010-06-11 | 2014-07-02 | Astrazeneca Ab | مركبات بيريميدينيل للاستخدام كمثبطات atr |
WO2012012307A1 (en) | 2010-07-22 | 2012-01-26 | Boehringer Ingelheim International Gmbh | Sulfonyl compounds which modulate the cb2 rece |
WO2012021696A1 (en) | 2010-08-11 | 2012-02-16 | Millennium Pharmaceuticals, Inc. | Heteroaryls and uses thereof |
US9062038B2 (en) | 2010-08-11 | 2015-06-23 | Millennium Pharmaceuticals, Inc. | Heteroaryls and uses thereof |
JP2013533318A (ja) | 2010-08-11 | 2013-08-22 | ミレニアム ファーマシューティカルズ, インコーポレイテッド | ヘテロアリールおよびその使用 |
AU2011308856B2 (en) | 2010-10-01 | 2015-04-23 | Novartis Ag | Manufacturing process for pyrimidine derivatives |
JP2013542941A (ja) | 2010-10-13 | 2013-11-28 | ミレニアム ファーマシューティカルズ, インコーポレイテッド | ヘテロアリールおよびその使用 |
WO2012058671A1 (en) | 2010-10-31 | 2012-05-03 | Endo Pharmaceuticals Inc. | Substituted quinazoline and pyrido-pyrimidine derivatives |
WO2012136622A1 (en) | 2011-04-04 | 2012-10-11 | Cellzome Limited | Dihydropyrrolo pyrimidine derivatives as mtor inhibitors |
CN102887867B (zh) * | 2011-07-21 | 2015-04-15 | 中国科学院上海药物研究所 | 一类三嗪类化合物、该化合物的制备方法及其用途 |
CA2842916A1 (en) * | 2011-07-26 | 2013-01-31 | Grunenthal Gmbh | Substituted heteroaromatic pyrazole-containing carboxamide and urea derivatives as vanilloid receptor ligands |
UA118010C2 (uk) | 2011-08-01 | 2018-11-12 | Вертекс Фармасьютікалз Інкорпорейтед | Інгібітори реплікації вірусів грипу |
WO2013030665A1 (en) * | 2011-09-02 | 2013-03-07 | Purdue Pharma L.P. | Pyrimidines as sodium channel blockers |
RU2616619C2 (ru) | 2011-09-21 | 2017-04-18 | Селлзоум Лимитед | Морфолино-замещенные производные мочевины или карбамата в качестве ингибиторов mtor |
AU2012320465B2 (en) | 2011-10-07 | 2016-03-03 | Cellzome Limited | Morpholino substituted bicyclic pyrimidine urea or carbamate derivatives as mTOR inhibitors |
BR112014028881A2 (pt) | 2012-05-23 | 2017-06-27 | Hoffmann La Roche | populações de células, banco de células, métodos de obtenção de uma população de células, métodos de identificação de um fator, métodos de seleção, métodos de fornecimento de terapia, populações de hepatócitos e método de obtenção de células |
EP2803668A1 (en) | 2013-05-17 | 2014-11-19 | Boehringer Ingelheim International Gmbh | Novel (cyano-dimethyl-methyl)-isoxazoles and -[1,3,4]thiadiazoles |
US9296727B2 (en) | 2013-10-07 | 2016-03-29 | Vertex Pharmaceuticals Incorporated | Methods of regioselective synthesis of 2,4-disubstituted pyrimidines |
ME03460B (me) | 2013-11-13 | 2020-01-20 | Vertex Pharma | Inhibitori replikacije virusa influence |
BR112016010576B1 (pt) | 2013-11-13 | 2022-05-24 | Vertex Pharmaceuticals Incorporated | Métodos de preparação de inibidores de replicação do vírus da gripe |
EP3145916B1 (en) * | 2014-05-21 | 2020-02-12 | Allergan, Inc. | Imidazole derivatives as formyl peptide receptor modulators |
CN106661002B (zh) | 2014-08-04 | 2021-06-29 | 纽韦卢森公司 | 用于治疗炎性、代谢性、肿瘤性和自身免疫性疾病的嘧啶衍生物 |
JP6704416B2 (ja) | 2015-05-13 | 2020-06-03 | バーテックス ファーマシューティカルズ インコーポレイテッドVertex Pharmaceuticals Incorporated | インフルエンザウイルスの複製の阻害剤を調製する方法 |
MA42422A (fr) | 2015-05-13 | 2018-05-23 | Vertex Pharma | Inhibiteurs de la réplication des virus de la grippe |
TW201815787A (zh) | 2016-09-23 | 2018-05-01 | 美商基利科學股份有限公司 | 磷脂醯肌醇3-激酶抑制劑 |
TW201813963A (zh) | 2016-09-23 | 2018-04-16 | 美商基利科學股份有限公司 | 磷脂醯肌醇3-激酶抑制劑 |
TW201825465A (zh) | 2016-09-23 | 2018-07-16 | 美商基利科學股份有限公司 | 磷脂醯肌醇3-激酶抑制劑 |
WO2018218197A2 (en) | 2017-05-26 | 2018-11-29 | Board Of Regents, The University Of Texas System | Tetrahydropyrido[4,3-d]pyrimidine inhibitors of atr kinase |
EP3651768B1 (en) | 2017-07-13 | 2023-12-20 | Board of Regents, The University of Texas System | Heterocyclic inhibitors of atr kinase |
JP7290627B2 (ja) | 2017-08-17 | 2023-06-13 | ボード オブ レジェンツ,ザ ユニバーシティ オブ テキサス システム | Atrキナーゼの複素環式阻害剤 |
JP7341156B2 (ja) | 2018-03-16 | 2023-09-08 | ボード オブ レジェンツ,ザ ユニバーシティ オブ テキサス システム | Atrキナーゼの複素環式阻害剤 |
AU2020405446A1 (en) | 2019-12-20 | 2022-05-26 | Nuevolution A/S | Compounds active towards nuclear receptors |
AU2021249530A1 (en) | 2020-03-31 | 2022-12-01 | Nuevolution A/S | Compounds active towards nuclear receptors |
JP2023519603A (ja) | 2020-03-31 | 2023-05-11 | ヌエヴォリューション・アクティーゼルスカブ | 核内受容体に対して活性な化合物 |
Family Cites Families (44)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE3922735A1 (de) | 1989-07-11 | 1991-01-24 | Hoechst Ag | Aminopyrimidin-derivate, verfahren zu ihrer herstellung, sie enthaltende mittel und ihre verwendung als fungizide |
CN100345830C (zh) * | 2000-04-27 | 2007-10-31 | 安斯泰来制药有限公司 | 稠合杂芳基衍生物 |
JP3810017B2 (ja) * | 2000-04-27 | 2006-08-16 | アステラス製薬株式会社 | 縮合ヘテロアリール誘導体 |
AU2790502A (en) * | 2000-11-10 | 2002-05-21 | Hoffmann La Roche | Pyrimidine derivatives and their use as neuropeptide y receptor ligands |
DK2316831T3 (da) * | 2002-11-21 | 2013-06-10 | Novartis Ag | 2-(Morpholin-4-yl)pyrimidiner som phosphotidylinositol (PI)-3-kinaseinhibitorer samt deres anvendelse ved behandling af cancer |
WO2005000404A2 (en) | 2003-05-29 | 2005-01-06 | Synta Pharmaceuticals, Corp. | Heterocyclic compounds for preventing and treating disorders associated with excessive bone loss |
GB0415365D0 (en) * | 2004-07-09 | 2004-08-11 | Astrazeneca Ab | Pyrimidine derivatives |
GB0415364D0 (en) * | 2004-07-09 | 2004-08-11 | Astrazeneca Ab | Pyrimidine derivatives |
GB0415367D0 (en) * | 2004-07-09 | 2004-08-11 | Astrazeneca Ab | Pyrimidine derivatives |
US7772271B2 (en) * | 2004-07-14 | 2010-08-10 | Ptc Therapeutics, Inc. | Methods for treating hepatitis C |
WO2007084413A2 (en) | 2004-07-14 | 2007-07-26 | Ptc Therapeutics, Inc. | Methods for treating hepatitis c |
CA2586870A1 (en) * | 2004-11-10 | 2006-05-18 | Synta Pharmaceuticals Corp. | Il-12 modulatory compounds |
WO2006124874A2 (en) | 2005-05-12 | 2006-11-23 | Kalypsys, Inc. | Inhibitors of b-raf kinase |
TW200720256A (en) * | 2005-05-13 | 2007-06-01 | Synta Pharmaceuticals Corp | IL-12 modulatory compounds |
NZ563774A (en) | 2005-05-20 | 2010-04-30 | Methylgene Inc | Inhibitors of VEGF receptor and HGF receptor signaling |
DE102005024494A1 (de) * | 2005-05-27 | 2006-11-30 | Bayer Healthcare Ag | Verwendung von Cyanopyrimidinen |
AU2006265840B2 (en) | 2005-07-01 | 2010-02-11 | Irm Llc | Pyrimidine-substituted benzimidazole derivatives as protein kinase inhibitors |
WO2007013691A1 (ja) | 2005-07-29 | 2007-02-01 | Takeda Pharmaceutical Company Limited | スピロ環化合物 |
WO2007027855A2 (en) * | 2005-09-01 | 2007-03-08 | Array Biopharma Inc. | Raf inhibitor compounds and methods of use thereof |
JP4531027B2 (ja) | 2005-09-29 | 2010-08-25 | 田辺三菱製薬株式会社 | 医薬組成物 |
JP2007091649A (ja) | 2005-09-29 | 2007-04-12 | Taisho Pharmaceut Co Ltd | ピリミジン誘導体及びその使用に関連する治療方法 |
KR101487027B1 (ko) | 2005-09-30 | 2015-01-28 | 미카나 테라퓨틱스, 인크. | 치환된 피라졸 화합물 |
NZ567133A (en) | 2005-09-30 | 2011-07-29 | Vertex Pharma | Deazapurines useful as inhibitors of janus kinases |
GB2431156A (en) | 2005-10-11 | 2007-04-18 | Piramed Ltd | 1-cyclyl-3-substituted- -benzenes and -azines as inhibitors of phosphatidylinositol 3-kinase |
GB0520657D0 (en) * | 2005-10-11 | 2005-11-16 | Ludwig Inst Cancer Res | Pharmaceutical compounds |
BRPI0618011A2 (pt) | 2005-10-28 | 2011-08-16 | Astrazeneca Ab | composto ou um sal farmaceuticamente aceitável do mesmo, processo para a preparação do mesmo, composição farmacêutica, uso de um composto ou um sal farmaceuticamente aceitável do mesmo, e, métodos para produzir um efeito anti-proliferativo e um efeito pró-apoptósico em um animal de sangue quente, para tratar doença e para produzir um efeito inibidor de jak em um animal de sangue quente |
WO2007063868A1 (ja) | 2005-11-29 | 2007-06-07 | Toray Industries, Inc. | アリールメチレンウレア誘導体及びその用途 |
GB0525080D0 (en) | 2005-12-09 | 2006-01-18 | Astrazeneca Ab | Pyrimidine derivatives |
GB0525081D0 (en) | 2005-12-09 | 2006-01-18 | Astrazeneca Ab | Pyrimidine derivatives |
GB0525083D0 (en) | 2005-12-09 | 2006-01-18 | Astrazeneca Ab | Pyrimidine derivatives |
NL2000323C2 (nl) | 2005-12-20 | 2007-11-20 | Pfizer Ltd | Pyrimidine-derivaten. |
AU2007204208A1 (en) | 2006-01-11 | 2007-07-19 | Astrazeneca Ab | Morpholino pyrimidine derivatives and their use in therapy |
JO2660B1 (en) | 2006-01-20 | 2012-06-17 | نوفارتيس ايه جي | Pi-3 inhibitors and methods of use |
AU2007209928B2 (en) | 2006-01-30 | 2013-03-28 | Exelixis, Inc. | 4-aryl-2-amino-pyrimidines or 4-aryl-2-aminoalkyl-pyrimidines as JAK-2 modulators and pharmaceutical compositions containing them |
EP2008210A1 (en) | 2006-03-15 | 2008-12-31 | Csir | Modulation of phosphoryl transferase activity of glutamine synthetase |
JP5243696B2 (ja) | 2006-03-17 | 2013-07-24 | 田辺三菱製薬株式会社 | ベンゼン誘導体 |
WO2007114323A1 (ja) | 2006-04-04 | 2007-10-11 | Taisho Pharmaceutical Co., Ltd. | アミノピロリジン化合物 |
RU2008145225A (ru) | 2006-04-19 | 2010-05-27 | Новартис АГ (CH) | Соединения индазола и способы ингибирования cd7 |
WO2007126043A1 (ja) | 2006-04-27 | 2007-11-08 | Mitsubishi Tanabe Pharma Corporation | チアゾール環を含むカルボン酸誘導体の医薬用途 |
GB0610909D0 (en) | 2006-06-05 | 2006-07-12 | Merck Sharp & Dohme | Therapeutic treatment |
WO2008005538A2 (en) | 2006-07-05 | 2008-01-10 | Exelixis, Inc. | Methods of using igf1r and abl kinase modulators |
WO2008023180A1 (en) | 2006-08-24 | 2008-02-28 | Astrazeneca Ab | Morpholino pyrimidine derivatives useful in the treatment of proliferative disorders |
KR101435231B1 (ko) | 2006-08-24 | 2014-10-02 | 아스트라제네카 아베 | 증식성 질환의 치료에 유용한 모르폴리노 피리미딘 유도체 |
WO2008125833A1 (en) | 2007-04-12 | 2008-10-23 | Piramed Limited | Pharmaceutical compounds |
-
2007
- 2007-08-21 KR KR1020097005961A patent/KR101435231B1/ko active IP Right Grant
- 2007-08-21 JP JP2009525103A patent/JP5534811B2/ja not_active Expired - Fee Related
- 2007-08-21 EP EP07789273A patent/EP2057140B1/en active Active
- 2007-08-21 AU AU2007287428A patent/AU2007287428B2/en not_active Ceased
- 2007-08-21 WO PCT/GB2007/003173 patent/WO2008023159A1/en active Application Filing
- 2007-08-21 CA CA002660758A patent/CA2660758A1/en not_active Abandoned
- 2007-08-21 MX MX2009002046A patent/MX2009002046A/es active IP Right Grant
- 2007-08-22 CL CL200702446A patent/CL2007002446A1/es unknown
- 2007-08-23 US US11/844,092 patent/US7750003B2/en not_active Expired - Fee Related
- 2007-08-23 UY UY30559A patent/UY30559A1/es unknown
- 2007-08-24 PE PE2007001151A patent/PE20081362A1/es not_active Application Discontinuation
- 2007-08-24 AR ARP070103775A patent/AR062526A1/es not_active Application Discontinuation
-
2009
- 2009-02-10 NO NO20090631A patent/NO20090631L/no not_active Application Discontinuation
- 2009-02-11 IL IL196998A patent/IL196998A0/en unknown
- 2009-02-20 CO CO09017337A patent/CO6150160A2/es unknown
- 2009-09-18 HK HK09108580.0A patent/HK1130776A1/xx not_active IP Right Cessation
Also Published As
Publication number | Publication date |
---|---|
AU2007287428B2 (en) | 2011-08-11 |
JP2010501534A (ja) | 2010-01-21 |
CO6150160A2 (es) | 2010-04-20 |
JP5534811B2 (ja) | 2014-07-02 |
AU2007287428A1 (en) | 2008-02-28 |
PE20081362A1 (es) | 2008-11-14 |
US7750003B2 (en) | 2010-07-06 |
CL2007002446A1 (es) | 2008-04-04 |
EP2057140B1 (en) | 2012-08-08 |
WO2008023159A1 (en) | 2008-02-28 |
KR20090053928A (ko) | 2009-05-28 |
MX2009002046A (es) | 2009-03-06 |
IL196998A0 (en) | 2009-11-18 |
HK1130776A1 (en) | 2010-01-08 |
US20080171743A1 (en) | 2008-07-17 |
EP2057140A1 (en) | 2009-05-13 |
AR062526A1 (es) | 2008-11-12 |
KR101435231B1 (ko) | 2014-10-02 |
NO20090631L (no) | 2009-03-16 |
CA2660758A1 (en) | 2008-02-27 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
UY30559A1 (es) | Derivados de morfolino pirimidina, procesos de preparacion, composiciones conteniéndolos y aplicaciones | |
CO6390066A2 (es) | Derivados de pirimidina trisustituida para el tratamiento de enfermedades proliferativas | |
CO6251364A2 (es) | Derivados de morfolino pirimidina utilazdos en enfermedades relacionados con mtor quinasa y/o p13k | |
NI201000003A (es) | Derivados de pirimidina trisustituida para el tratamiento de enfermedades proliferativas. | |
UY30819A1 (es) | Derivados de pirazol, composiciones farmacéuticas conteniéndolos, procesos de preparacion y aplicaciones | |
UY29199A1 (es) | Derivados tiazol, composiciones que los contienen, procedimientos de preparación y aplicaciones | |
UY32158A (es) | Derivados heterociclicos y metodos de uso de los mismos | |
CL2008003873A1 (es) | Compuestos derivados de benzofuropirimidinona sustituidos, inhibidores de proteinas quinasas; composicion farmaceutica que comprende a uno de los compuestos; metodo para inhibir in vitro proteinas quinasa (pim, cdc7,ck2); y uso de los compuestos en la preparacion de medicamentos para el tratamiento del cancer | |
CL2009000483A1 (es) | Compuestos derivados de n-(piridin-3-il)-1,3-tiazol-5-amino-4-carboxamida, inhibidores de cinasa pim; composicion farmaceutica; y uso para el tratamiento del cancer. | |
CL2011003082A1 (es) | Compuestos derivados de [1,2,4]triazolo[1,5-a]piridina, inhibidores de jak2 o fak; composiciones farmaceuticas que los comprenden; y su uso para el tratamiento de una enfermedad hiperproliferativa. | |
CL2011000589A1 (es) | Compuestos derivados de pirrolidin-2-carboxamida, inhibidores de la interaccion p53-mdm2; composicion farmaceutica que los comprende; y su uso en la preparacion de medicamentos utiles para el tratamiento del cancer. | |
CO6290656A2 (es) | Derivados heterociclicos de urea y metodos de uso de los mismos -211 | |
CL2007001435A1 (es) | Compuestos derivados de fenilalanina; proceso de prepatacion; composicion farmaceutica que comprende a dicho compuesto; y uso del compuesto como inhibidores de integrina para el tratamiento del cancer. | |
UY29087A1 (es) | Derivados de adamantilo, composiciones farmaceuticas que los contienen, procesos para su preparacion y uso terapeutico | |
ECSP088974A (es) | Derivados de imidazol pirimidina para el tratamiento de enfermedades relacionadas con la glicógeno sintasa quinasa (gsk3) | |
ECSP11011113A (es) | Piridiloxi-indoles inhibidores del vegf-r2 y uso de los mismos para el tratamiento de enfermedades | |
DOP2011000203A (es) | Derivados de pirimidin indol para el tratamiento de cancer | |
UY30809A1 (es) | Derivados de n-[3-[4-fenil)piperidin-1-carbonil]fenil]sulfonamidas sustituidas, procesos de preparacion y aplicaciones | |
UY32315A (es) | Compuestos de piperidina y usos de los mismo-596 | |
CL2008001297A1 (es) | N-[(1s)-1-(5-fluoropirim idin-2-i1 )etil]-3-(5-isopropoxi-1 h-pirazol-3-il )-3h-imidazo[4,5-b]piridin-5amina o una sal farmacéuticamente aceptabie del mismo; composición farmacéutica que lo comprende; y su uso en el tratamiento del cáncer. | |
UY31141A1 (es) | Compuestos de piperidina y sus usos | |
UY29370A1 (es) | Derivados de tiazol, composiciones que lo contienen, procedimientos de preparación y aplicaciones | |
UY30544A1 (es) | Compuestos de pirrolo-piperidina y sales farmacéuticametne aceptables de los mismos, procesos de fabricacion, composiciones y aplicaciones | |
UY31864A (es) | Derivados de urea hetericíclica y métodos de uso de los mismos-332 | |
CL2007003251A1 (es) | Compuestos derivados de 1h-pirazoles sustituidos, inhibidores de reacciones catalizadas por una quinasa; su procedimiento de preparacion; composicion farmaceutica; compuestos intermediarios; uso de los compuestos principales, utiles en el tratamiento del cancer. |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
DESI | Application deemed to be withdrawn |
Effective date: 20120606 |